We enable the acceleration of life science research
and development in the pursuit of improved human health
Cellvera is a biopharmaceutical company focused on discovering, developing and commercializing oral therapies and monitoring tools to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleotide chemistry, biology, biochemistry and virology, Cellvera has built a nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV).
Global Response Aid (GRA)
At the stage where COVID-19 was declared a pandemic, we quickly deployed a crew to start an initiative, that later became a full-fledged company called Global Response Aid. Alongside Agility which is one of the world’s leading logistics companies with a presence in 100 countries and annual turnover of $5BN.